Indeed, CD70 expression is an independent predictor of poor OS for patients with low-grade gliomas (LGG) and GBM, correlating with chemokine-mediated immune modulation, tumor aggressiveness and immunosuppression via tumor-associated M2 macrophage recruitment/activation in GBM (142). Here, CD70 is linked to neoplasm.